Quantcast
Last updated on April 16, 2014 at 11:32 EDT

OBN Adds World Class Pharma and VC Figures to its Thematic Advisory Panels

June 25, 2012

OXFORD, England, June 26, 2012 /PRNewswire/ –

OBN, the not-for-profit business network which provides comprehensive support for
bioscience businesses in the ‘Golden Triangle’ biocluster and beyond, is pleased to
announce that it has established two new high level Advisory Panels. The two Boards draw
on leading experts from across the industry and have been created in order to maintain
OBN’s leadership position in program development at BioTrinity, Europe’s 3rd Largest
Annual Partnering and Investment Conference.

The Business Development and Licensing (BD&L) Advisory Panel contains participants
from big pharma through to small biotech BD&L executives, including Amgen, Astellas Pharma
Europe, Biogen Idec, Bristol-Myers Squibb, Crescendo Biologics, Kymab, Polytherics,
Prosidion, Shire and Takeda Pharmaceuticals Europe.

Dr Jon Rees, CEO of OBN, said: “Only by listening to key industry executives embedded
in the deal-making and licensing environment can we respond to the needs and interests of
the members in our network and continue to deliver cutting edge content to the
participants at our networking events and conferences.”

The Investor Advisory Panel draws on BioTrinity’s long-standing role of bringing a
wide range of international investors together with R&D companies. It includes
participants from the UK, Europe and the US and from traditional venture capital and the
corporate venturing worlds. Members include 3i plc, Abbott Biotech Ventures, Apposite
Capital LLP, Boehringer Ingelheim Venture Fund GmbH, Credit Agricole Private Equity
(CAPE), Edmond de Rothschild Investment Partners, Index Ventures, MedImmune Ventures,
Merck Serono Ventures, Sofinnova Partners, SR One (GSK), and Takeda Ventures.

Already the panel participants have given their first round of feedback and
suggestions for next year’s BioTrinity panels and this will be developed to release the
preliminary BioTrinity 2013 program in December 2012. Combined with OBN’s recent ‘Life
Sciences, New Money’ series of networking events and breakfasts in London, Cambridge and
Oxford, the advanced program development for BioTrinity 2013 maintains OBN’s leadership
position in providing comprehensive support for the UK bioindustry.

Dr Jon Rees, CEO of OBN, said: “I am delighted with the levels of energy and
commitment the investment community, our 200 members, the wider industry and my team are
feeding into ensuring our offer continues to be more relevant and more exciting than ever.
This synergy will benefit us all.”

About OBN

OBN is a not-for-profit business network which provides comprehensive support for its
member biotech and medtech companies in the Oxford and South-East England biocluster and
the rest of the UK. Our activities can be summarised as networking, partnering, group
purchasing, and fundraising advice. Through its delivery of Europe’s fastest growing
biopartnering and investment conference, BioTrinity, OBN generates more
R&D-company-to-investor interactions than anyone else in Europe. OBN is sponsored by
Shire, as Corporate Patron, and Corporate Sponsors MEPC, Manches LLP, James Cowper, George
James, Ernst & Young, Interea International, SRG, FOCUS Insurance, Ardington Archives,
World Courier and Citigate Dewe Rogerson as well as by its extensive membership of R&D
companies and other companies across the entire life sciences industry ecosystem. OBN
counts more than 200 companies amongst its membership, which is growing over 40% per year.

For further information on OBN and its activities, please visit:

http://www.obn.org.uk

About the Advisory Panels

The two Advisory Panels contain representatives from the following companies:

Investors

Credit Agricole Private Equity (CAPE), GlaxoSmithKline, Edmond de Rothschild
Investment Partners (EdRIP), MedImmune Ventures, 3i plc, Apposite Capital LLP, Index
Ventures, Boehringer Ingelheim Venture Fund GmbH, Sofinnova Partners, Merck Serono
Ventures, Abbott Biotech Ventures, SR One (GlaxoSmithKline), GlaxoSmithKline, Takeda
Ventures.

Business Development and Licensing

Amgen, Astellas Pharma Europe, Biogen Idec, Bristol-Myers Squibb, Crescendo Biologics,
Kymab, Prosidion , Shire, Takeda Pharmaceuticals Europe, Polytherics.

        Contacts

        OBN
        Andy Smith, Director of Investor Relations and PR
        Tel: +44(0)845-5049715
        andy.smith@obn.org.uk

        Citigate Dewe Rogerson
        Chris Gardner/Nina Enegren
        T: +44(0)20-7638-9571
        chris.gardner@citigatedr.co.uk / nina.enegren@citigatedr.co.uk
         [helena.galilee@citigatedr.co.uk ]

SOURCE OBN


Source: PR Newswire